Zobrazeno 1 - 10
of 31
pro vyhledávání: '"G. K. Schwartz"'
Publikováno v:
Sarcoma, Vol 2015 (2015)
Externí odkaz:
https://doaj.org/article/749392d6d05044cfac256e6c00cd77d7
Publikováno v:
Sarcoma, Vol 2014 (2014)
Sarcomas are heterogeneous malignant tumors of mesenchymal origin characterized by more than 100 distinct subtypes. Unfortunately, 25–50% of patients treated with initial curative intent will develop metastatic disease. In the metastatic setting, c
Externí odkaz:
https://doaj.org/article/f4d00a735ecc46b48a05f16cddde7b90
Publikováno v:
Cancer gene therapy. 24(9)
Peptide nucleic acid (PNA) oligomers are DNA mimics, which are capable of binding gene sequences 1000-fold more avidly than complementary native DNA by strand invasion and effectively obstruct transcription. Irreversibly obstructing the transcription
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb1903a16d6a92edc53890d358e682b0
https://pubmed.ncbi.nlm.nih.gov/28937091
https://pubmed.ncbi.nlm.nih.gov/28937091
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(12)
CPT-11, a DNA topoisomerase I inhibitor, has demonstrated clinical activity in colorectal cancer. Flavopiridol, a cyclin-dependent kinase inhibitor, is rapidly emerging as a chemotherapy modulator. To enhance the therapeutic index of CPT-11 in colon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c72fcce4bd83fd6d0f16ebd4084f973e
https://pubmed.ncbi.nlm.nih.gov/11751522
https://pubmed.ncbi.nlm.nih.gov/11751522
Autor:
S, Sharma, N, Kemeny, G K, Schwartz, D, Kelsen, E, O'Reilly, D, Ilson, J, Coyle, R L, De Jager, M P, Ducharme, S, Kleban, E, Hollywood, L B, Saltz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(12)
Exatecan mesylate (DX-8951f) is a topoisomerase I inhibitor that has increased solubility and antitumor activity compared with other topoisomerase I inhibitors. The purpose of this study was to establish a safe dose of DX-8951f given as a weekly 24-h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ea50f09f6238189b232cb745caf4f82
https://pubmed.ncbi.nlm.nih.gov/11751488
https://pubmed.ncbi.nlm.nih.gov/11751488
Autor:
M A, Shah, G K, Schwartz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(8)
The concept of combining chemotherapeutic agents to increase cytotoxic efficacy has evolved greatly over the past several years. The rationale for combination chemotherapy has centered, in the past, on attacking different biochemical targets, overcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7bb8450c4d94667132239e1ae34df9f1
https://pubmed.ncbi.nlm.nih.gov/11489790
https://pubmed.ncbi.nlm.nih.gov/11489790
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(8)
As a single agent, gemcitabine (2',2'-difluorodeoxycytidine) has shown minimal activity against gastrointestinal malignancies with only a modest improvement in survival in patients with pancreatic cancer. Recently, gemcitabine resistance has been ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::11a134d54dff7aa2bbef5b10892a373b
https://pubmed.ncbi.nlm.nih.gov/11489836
https://pubmed.ncbi.nlm.nih.gov/11489836
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(3)
E2F-1 regulates the transcription of genes required for DNA synthesis. Previously, we have reported that UCN-01 suppresses E2F-1 protein expression without any noticeable effect on its mRNA level in gastric cancer cell line SK-GT5 (Clin. Cancer Res.,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2e19040f06a0a499209310f11b4d4f86
https://pubmed.ncbi.nlm.nih.gov/11297263
https://pubmed.ncbi.nlm.nih.gov/11297263
Autor:
A, Kaubisch, G K, Schwartz
Publikováno v:
Cancer journal (Sudbury, Mass.). 6(4)
Malignant cells have acquired adaptations, which give them a growth and survival advantage over normal cells. One effect of many of these adaptations is that many cancerous cells are less likely to undergo programmed cell death (apoptosis) and, moreo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ae26dd5f3864177fa30d08cd98fa8ec
https://pubmed.ncbi.nlm.nih.gov/11038138
https://pubmed.ncbi.nlm.nih.gov/11038138
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
Autor:
J A, Koutcher, M, Motwani, K L, Zakian, X K, Li, C, Matei, J P, Dyke, D, Ballon, H H, Yoo, G K, Schwartz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(4)
Pretreatment of tumor cells with the protein kinase C (PKC) inhibitor bryostatin-1 enhances the cytotoxicity of most chemotherapeutic agents. However, in the case of paclitaxel, this effect has been shown in vitro to be best achieved when bryostatin-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::49cc9bdf83f17af0a5b5afcfabcd4ec1
https://pubmed.ncbi.nlm.nih.gov/10778982
https://pubmed.ncbi.nlm.nih.gov/10778982